keyword
MENU ▼
Read by QxMD icon Read
search

GVHD

keyword
https://www.readbyqxmd.com/read/29791053/impact-of-ruxolitinib-pretreatment-on-outcomes-after-allogeneic-stem-cell-transplantation-in-patients-with-myelofibrosis
#1
Sharifah Shahnaz Syed Abd Kadir, Maximilian Christopeit, Wulf Gerald, Eva Wagner, Martin Bornhauser, Thomas Schroeder, Martina Crysandt, Karin Mayer, Julia Jonas, Matthias Stelljes, Anita Badbaran, Francis Ayuketang Ayuk, Ioanna Triviai, Dominik Wolf, Christine Wolschke, Nicolaus Kröger
INTRODUCTION: Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown. PATIENTS AND METHODS: We reported on 159 myelofibrosis patients (pts) with a median age of 59 years (r: 28 - 74) who received reduced intensity ASCT between 2000 and 2015 in 8 German centers from related (n = 23), matched (n=86) or mismatched (n=50) unrelated donors. Forty-six (29%) patients received ruxolitinib at any time point prior to ASCT...
May 23, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29789652/small-hypoxia-primed-mesenchymal-stem-cells-attenuate-graft-versus-host-disease
#2
YongHwan Kim, Hye Jin Jin, Jinbeom Heo, Hyein Ju, Hye-Yeon Lee, Sujin Kim, Seungun Lee, Jisun Lim, Sang Young Jeong, JiHye Kwon, Miyeon Kim, Soo Jin Choi, Wonil Oh, Yoon Sun Yang, Hyun Ho Hwang, Hwan Yeul Yu, Chae-Min Ryu, Hong Bae Jeon, Dong-Myung Shin
Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases due to their immunosuppressive capacity. Here, we show that Small MSCs primed with Hypoxia and Calcium ions (SHC-MSCs) exhibit enhanced stemness and immunomodulatory functions for treating allogeneic conflicts. Compared with naïve cultured human umbilical cord blood-derived MSCs, SHC-MSCs were resistant to passage-dependent senescence mediated via the monocyte chemoattractant protein-1 and p53/p21 cascade and secreted large amounts of pro-angiogenic and immunomodulatory factors, resulting in suppression of T-cell proliferation...
May 22, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29785172/graft-versus-host-disease-from-basic-pathogenic-principles-to-dna-damage-response-and-cellular-senescence
#3
REVIEW
Adam Kuba, Ludek Raida
Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). Despite a huge progress in HSCT techniques and posttransplant care, GVHD remains a significant obstacle in successful HSCT outcome. This review presents a complex summary of GVHD pathogenesis with focus on references considering basic biological processes such as DNA damage response and cellular senescence.
2018: Mediators of Inflammation
https://www.readbyqxmd.com/read/29781812/pim-2-protein-kinase-negatively-regulates-t-cell-responses-in-transplantation-and-tumor-immunity
#4
Anusara Daenthanasanmak, Yongxia Wu, Supinya Iamsawat, Hung D Nguyen, David Bastian, MengMeng Zhang, M Hanief Sofi, Shilpak Chatterjee, Elizabeth G Hill, Shikhar Mehrotra, Andrew S Kraft, Xue-Zhong Yu
PIM kinase family members play a crucial role in promoting cell survival and proliferation via phosphorylation of their target substrates. In this study, we investigated the role of the PIM kinases with respect to T cell responses in transplantation and tumor immunity. We found that the PIM-2 isoform negatively regulated T cell responses to alloantigen, in contrast to the PIM-1 and PIM-3 isoforms, which acted as positive regulators. T cells deficient in PIM-2 demonstrated increased T cell differentiation toward Th1 subset, proliferation, and migration to target organs after allogeneic bone marrow transplantation, resulting in dramatically accelerated graft-versus-host disease (GVHD) severity...
May 21, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29779324/-application-of-low-dose-atg-for-gvhd-prophylaxis-in-patients-undergoing-pbsct-aged-over-forty-years-old
#5
C Liang, E L Jiang, J F Yao, Q L Ma, W H Zhai, A M Pang, Y Huang, J L Wei, S Z Feng, M Z Han
Objective: To explore the effectiveness of a novel GVHD prophylaxis regimen containing low-dose anti-T lymphocyte globulin (ATG) in patients undergoing peripheral blood stem cell transplantation (PBSCT) from HLA-matched sibling donors (MSD) given both the patients and donors were aged over forty years old. Methods: From March 2013 to April 2017, 98 patients with hematologic malignancies were enrolled in the study. Standard GVHD prophylaxis consisted of the administration of cyclosporine A/tacrolimus and a short course of methotrexate...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29779322/-impact-of-mycophenolate-mofetil-prophylaxis-duration-on-acute-graft-versus-host-disease-after-haploidentical-stem-cell-transplantation
#6
Y Q Sun, X J Huang, L P Xu, X H Zhang, C H Yan, K Y Liu, Y Wang
Objective: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using 'Beijing Protocol'. Methods: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day -9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day -9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29778715/photopheresis-of-a-less-than-10-kg-child-with-acute-graft-versus-host-disease-accompanied-with-hyperbilirubinemia-a-case-report
#7
REVIEW
Ashraf Malek Mohammadi, Amir Hossein Norooznezhad, Jerard Seghatchian, Mohsen Nikbakht, Farhad Heshmati, Saeed Mohammadi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Hematopoietic stem cell transplantation is a curative treatment for many hematologic malignancies with its most important side effect being graft-versus-host disease (GVHD). Herein, we present a 3.5 year-old male with weight of 9.8 kg with acute GVHD (grade IV gastrointestinal and cutaneous) who did not respond to the first line therapies (corticosteroids). Thus, the patient was a candidate for extracorporeal photochemotherapy (ECP). Due to the hyperbilirubinemia, two sessions of ECP every week as well as one session of plasmapheresis 24 h before each ECP session were performed (Spectra™ Optia® apheresis system)...
May 9, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29778713/concluding-commentary-on-current-trends-to-enhance-the-clinical-safety-of-pediatric-transfusion-focusing-on-prevention-of-untoward-complications-of-hsc-transplantation-newer-strategies-for-improving-the-standards-of-safety-quality-of-stem-cells-expansion-for
#8
REVIEW
Irena Sniecinski, Jerard Seghatchian
Clinical practice and related diagnostic, development and research [DDR] strategies in pediatric transfusion and transplantation cover a broad range of multidisciplinary studies, performed by many professionals involved in this most challenging clinical field [1]. This commentary on the current position and future perspectives in pediatric transfusion field is aimed to highlight major unresolved transfusion complications in pediatric patients, namely red blood cell and platelet alloimmunisation, and new ones such as nosocomial infection, thrombosis and multi-organ failure...
May 16, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29773281/-cutaneous-and-systemic-t-cell-lymphoma-treated-with-haploidentical-bone-marrow-transplantation
#9
M Méchineaud, M Mercier, Y Le Corre, A Croué, N Ifrah, L Martin
BACKGROUND: Herein, we report a case of systemic cutaneous T-cell lymphoma refractory to standard therapy, the course of which resulted in haplo-identical bone marrow grafting. PATIENTS AND METHODS: A 53-year-old woman consulted for facial erythema with infiltration, keratotic lesions on the trunk, and adenopathies measuring around 1cm on the axilla and inguinal folds. A diagnosis was made of Sézary syndrome (SS), a leukaemic form of epidermotropic cutaneous T-cell lymphoma...
May 14, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29770447/effectiveness-of-immunoglobulin-prophylaxis-in-reducing-clinical-complications-of-hematopoietic-stem-cell-transplantation-a-systematic-review-and-meta-analysis
#10
REVIEW
Hilalion Ahn, Jason Tay, Beverley Shea, Brian Hutton, Risa Shorr, Greg A Knoll, Donald William Cameron, Juthaporn Cowan
BACKGROUND: Prophylactic immunoglobulin has been used with varying efficacy to reduce complications in hematopoietic stem cell transplant recipients. STUDY DESIGN AND METHODS: A systematic review and meta-analysis was conducted of randomized controlled trials that assessed clinical outcomes (overall survival, transplant-related mortality, graft-versus-host disease [GVHD], veno-occlusive disease [VOD], interstitial pneumonitis, disease relapse, cytomegalovirus [CMV] infection and disease, non-CMV infection) of immunoglobulin prophylaxis versus placebo in hematopoietic stem cell transplant recipients...
May 16, 2018: Transfusion
https://www.readbyqxmd.com/read/29770141/unraveling-the-mechanisms-of-cutaneous-graft-versus-host-disease
#11
REVIEW
Pedro Santos E Sousa, Clare L Bennett, Ronjon Chakraverty
The skin is the most common target organ affected by graft-versus-host disease (GVHD), with severity and response to therapy representing important predictors of patient survival. Although many of the initiating events in GVHD pathogenesis have been defined, less is known about why treatment resistance occurs or why there is often a permanent failure to restore tissue homeostasis. Emerging data suggest that the unique immune microenvironment in the skin is responsible for defining location- and context-specific mechanisms of injury that are distinct from those involved in other target organs...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29769782/graft-versus-host-disease-presenting-as-fibrosing-alopecia-in-a-pattern-distribution-a-model-for-pathophysiological-understanding-of-cicatricial-pattern-hair-loss
#12
Hudson Dutra Rezende, Maria Fernanda Reis Gavazzoni Dias, Ralph Michel Trüeb
A case of cutaneous graft versus host disease (GvHD) presenting as fibrosing alopecia in a pattern distribution (FAPD) is discussed, possibly providing a mechanistic model for a better understanding of the pathogenic events underlying cicatricial pattern hair loss. The implication of a follicular inflammation and fibrosis associated with patterned hair loss has emerged from several independent studies. Eventually, Zinkernagel and Trüeb reported a peculiar type of cicatricial pattern hair loss with histopathological features consistent with lichen planopilaris (LPP) associated with androgenetic alopecia (AGA)...
March 2018: International Journal of Trichology
https://www.readbyqxmd.com/read/29769260/bim-regulates-the-survival-and-suppressive-capability-of-cd8-foxp3-regulatory-t-cells-during-murine-gvhd
#13
Kimberle Agle, Benjamin G Vincent, Clint Piper, Ludovic Belle, Vivian Zhou, Warren Shlomchik, Jonathan S Serody, William R Drobyski
CD8+ Foxp3+ T cells (Tregs) are a potent regulatory population whose functional and ontological similarities to CD4+ Fox3+ T cells have not been well delineated. Using an experimental model of graft versus host disease (GVHD), we observed that CD8+ Tregs were significantly less potent than CD4+ Tregs for the suppression of GVHD. To define the mechanistic basis for this observation, we examined the T cell repertoire and the transcriptional profile of in vivo-derived CD4+ and CD8+ Tregs that emerged early during this disease...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29769208/infusion-of-alloanergized-donor-lymphocytes-after-cd34-selected-haploidentical-myeloablative-hematopoietic-stem-cell-transplantation
#14
Jeff K Davies, Lisa L Brennan, John Wingard, Christopher R Cogle, Neena Kapoor, Ami J Shah, Bimalangshu R Dey, Thomas R Spitzer, Marcos De Lima, Laurence Jn Cooper, Peter Thall, Richard E Champlin, Lee M Nadler, Eva C Guinan
PURPOSE: Allogeneic haematopoietic stem-cell transplantation (HSCT) is a curative treatment for many haematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) and delayed immune reconstitution. Alloanergization of donor T-cells is a simple approach to rebuild immunity whilst limiting GvHD after haploidentical HSCT but the optimal T-cell dose and impact on immune reconstitution remain unknown.  Experimental Design: We performed a multicentre Phase 1 trial of alloanergized donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical HSCT...
May 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29764770/haploidentical-stem-cell-transplantation-bone-marrow-vs-peripheral-blood
#15
REVIEW
Zafer Gulbas
Hematopoietic stem cells may be obtained by collection of bone marrow, mobilization and collection of peripheral blood stem cells or umbilical cord blood. Transplantation of peripheral blood hematopoietic cells has increased due to faster engraftment and practicability in both the related, unrelated or haploidentical setting. We reviewed the question of which stem cell source - bone marrow (BM) or peripheral blood (PBSC) - is the most suitable for individuals undergoing haploidentical stem cell transplantation...
April 19, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29763906/the-therapeutic-effect-of-icam-1-overexpressing-mesenchymal-stem-cells-on-acute-graft-versus-host-disease
#16
Bo Tang, Xue Li, Yuanlin Liu, Xiuhui Chen, Ximei Li, Yanan Chu, Heng Zhu, Weijiang Liu, Fenfen Xu, Fan Zhou, Yi Zhang
BACKGROUND/AIMS: Mesenchymal stem cells (MSCs) do not readily migrate to appropriate sites, and this creates a major obstacle for their use in the treatment of graft-versus-host disease (GVHD). Intercellular adhesion molecule-1 (ICAM-1) can guide the homing of various immune cells to the proper anatomical location within secondary lymphoid organs (SLOs), which are the major niches for generating immune responses or tolerance. MSCs rarely migrate to SLOs after intravenous infusion, and are constitutively low expression of ICAM-1...
May 7, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29763694/corneal-fluorescein-staining-and-ocular-symptoms-but-not-schirmer-test-are-useful-as-indicators-of-response-to-treatment-in-chronic-ocular-gvhd
#17
Francisco Amparo, Hasanain Shikari, Ujwala Saboo, Reza Dana
PURPOSE: To evaluate long-term ocular surface clinical signs and symptoms response to therapy in patients with chronic ocular GVHD. METHODS: Retrospective review and data modeling. We reviewed the records of post-bone marrow transplantation patients who were newly diagnosed with ocular GVHD and initiated therapy, and analyzed changes in symptoms (Ocular Surface Disease Index [OSDI]; Symptom Assessment in Dry Eye [SANDE]) and signs (corneal fluorescein staining [CFS]; Schirmer test)...
May 12, 2018: Ocular Surface
https://www.readbyqxmd.com/read/29760162/unrelated-cord-blood-transplantation-in-patients-with-acquired-refractory-aplastic-anemia-a-nationwide-phase-ii-study
#18
Regis Peffault de Latour, Sylvie Chevret, Charlotte Jubert, Anne Sirvent, Claire Galambrun, Annalisa Ruggeri, Virginie Gandemer, Jérôme Cornillon, Fanny Rialland, Jean-Hugues H Dalle, Edouard Forcade, Benedicte Bruno, Catherine Paillard, Pierre S Rorlich, Alexandra Salmon, Sabine Fürst, Flore Sicre de Fontbrune, Marie Therese Rubio, Jacques-Olivier Bay, Mohamad Mohty, Jerome Larghero, Eliane Gluckman, Gerard Socié
Outcomes remain poor for patients with refractory severe aplastic anemia (SAA). Alternative donor transplantation may be considered, but results from previous studies have not been encouraging. We conducted a prospective nationwide phase II study to assess the efficacy and safety of unrelated cord blood transplantation (CBT) in patients with refractory SAA (APCORD protocol, NCT 01343953). To demonstrate a significant difference in one-year survival from 20% (null hypothesis) to 50% (alternative hypothesis), we needed to include 25 transplanted patients...
May 14, 2018: Blood
https://www.readbyqxmd.com/read/29755481/-phage-transplantation-in-allotransplantation-possible-treatment-in-graft-versus-host-disease
#19
Andrzej Górski, Ewa Jończyk-Matysiak, Ryszard Międzybrodzki, Beata Weber-Dąbrowska, Jan Borysowski
Graft-versus-host disease, both acute and chronic (aGvHD, cGvHD) remains a major complication in patients undergoing hematopoietic cell transplantation (HCT) and a significant therapeutic challenge, as many patients do not respond adequately to presently available therapy. Increasing antimicrobial resistance has greatly revived interest in using bacterial viruses (phages) to combat antibiotic-resistant bacteria. In recent years, evidence has accumulated indicating that phages also have anti-inflammatory and immunomodulatory activities...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29753839/platelet-transfusion-refractoriness-in-single-unit-cord-blood-transplantation-for-adults-risk-factors-and-clinical-outcomes
#20
Susumu Tanoue, Takaaki Konuma, Seiko Kato, Maki Oiwa-Monna, Masamichi Isobe, Koji Jimbo, Satoshi Takahashi, Arinobu Tojo
Platelet transfusion refractoriness (PTR) is frequently observed after allogeneic hematopoietic cell transplantation (HCT). However, the incidence of and risk factors for PTR, and impact of PTR on transplant outcomes after cord blood transplantation (CBT) have not been fully investigated. We retrospectively analyzed 185 adult patients who received single-unit CBT in our institute. The mean 16-hour corrected count increment (CCI) for the 5,840 platelet transfusions was 3.68×109 /l. Among them, 3,196 transfusions (54...
May 10, 2018: Biology of Blood and Marrow Transplantation
keyword
keyword
11338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"